VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 588 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2015. The put-call ratio across all filers is 2.30 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2015 | $792,199,000 | -11.1% | 7,793,397 | +56.1% | 2.99% | -12.5% |
| Q3 2015 | $890,714,000 | -13.2% | 4,993,353 | +8.2% | 3.41% | -11.9% |
| Q2 2015 | $1,025,608,000 | +27.2% | 4,616,738 | +13.8% | 3.88% | +24.1% |
| Q1 2015 | $806,068,000 | -37.9% | 4,058,343 | -55.3% | 3.12% | -47.6% |
| Q4 2014 | $1,299,010,000 | -0.7% | 9,077,007 | -8.9% | 5.96% | +13.6% |
| Q3 2014 | $1,307,761,000 | -12.4% | 9,967,690 | -15.7% | 5.25% | -19.4% |
| Q2 2014 | $1,492,117,000 | +21.8% | 11,830,932 | +27.3% | 6.51% | +26.7% |
| Q1 2014 | $1,225,511,000 | +25.3% | 9,296,143 | +11.6% | 5.14% | +12.6% |
| Q4 2013 | $977,825,000 | +4.7% | 8,329,004 | -6.9% | 4.56% | -11.5% |
| Q3 2013 | $933,712,000 | +14.3% | 8,949,608 | -5.7% | 5.16% | +13.5% |
| Q2 2013 | $817,093,000 | – | 9,492,256 | – | 4.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |